Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine
Abstract TRIUMF is one of the only laboratories in the world able to produce both lead-203 (203Pb, t1/2 = 51.9 h) and 212Pb (t1/2 = 10.6 h) onsite via its 13 and 500 MeV cyclotrons, respectively. Together, 203Pb and 212Pb form an element-equivalent theranostic pair that potentiate image-guided, pers...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-37313-8 |
| _version_ | 1827910751099027456 |
|---|---|
| author | Brooke L. McNeil Simona A. Mastroianni Scott W. McNeil Stefan Zeisler Joel Kumlin Sogol Borjian Anthony W. McDonagh Michael Cross Paul Schaffer Caterina F. Ramogida |
| author_facet | Brooke L. McNeil Simona A. Mastroianni Scott W. McNeil Stefan Zeisler Joel Kumlin Sogol Borjian Anthony W. McDonagh Michael Cross Paul Schaffer Caterina F. Ramogida |
| author_sort | Brooke L. McNeil |
| collection | DOAJ |
| description | Abstract TRIUMF is one of the only laboratories in the world able to produce both lead-203 (203Pb, t1/2 = 51.9 h) and 212Pb (t1/2 = 10.6 h) onsite via its 13 and 500 MeV cyclotrons, respectively. Together, 203Pb and 212Pb form an element-equivalent theranostic pair that potentiate image-guided, personalized cancer treatment, using 203Pb as a single-photon emission computed tomography (SPECT) source, and 212Pb for targeted alpha therapy. In this study, improvements to 203Pb production were accomplished by manufacturing electroplated, silver-backed thallium (Tl) targets to improve target thermal stability, which allow for higher currents during irradiation. We implemented a novel, two-column purification method that employs selective Tl precipitation (203Pb only) alongside extraction and anion exchange chromatography to elute high specific activity and chemical purity 203/212Pb in a minimal volume of dilute acid, without the need for evaporation. Optimization of the purification method translated to improvements in radiolabeling yields and apparent molar activity of lead chelators TCMC (S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra(2-carbamoylmethyl)cyclododecane) and Crypt-OH, a derivative of a [2.2.2]-cryptand. |
| first_indexed | 2024-03-13T01:55:03Z |
| format | Article |
| id | doaj.art-00133871f67b43aeb202a5568bef9977 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-13T01:55:03Z |
| publishDate | 2023-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-00133871f67b43aeb202a5568bef99772023-07-02T11:15:53ZengNature PortfolioScientific Reports2045-23222023-06-0113111210.1038/s41598-023-37313-8Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicineBrooke L. McNeil0Simona A. Mastroianni1Scott W. McNeil2Stefan Zeisler3Joel Kumlin4Sogol Borjian5Anthony W. McDonagh6Michael Cross7Paul Schaffer8Caterina F. Ramogida9Life Sciences Division, TRIUMFLife Sciences Division, TRIUMFLife Sciences Division, TRIUMFARTMS Inc.ARTMS Inc.ARTMS Inc.Department of Chemistry, Simon Fraser UniversityARTMS Inc.Life Sciences Division, TRIUMFLife Sciences Division, TRIUMFAbstract TRIUMF is one of the only laboratories in the world able to produce both lead-203 (203Pb, t1/2 = 51.9 h) and 212Pb (t1/2 = 10.6 h) onsite via its 13 and 500 MeV cyclotrons, respectively. Together, 203Pb and 212Pb form an element-equivalent theranostic pair that potentiate image-guided, personalized cancer treatment, using 203Pb as a single-photon emission computed tomography (SPECT) source, and 212Pb for targeted alpha therapy. In this study, improvements to 203Pb production were accomplished by manufacturing electroplated, silver-backed thallium (Tl) targets to improve target thermal stability, which allow for higher currents during irradiation. We implemented a novel, two-column purification method that employs selective Tl precipitation (203Pb only) alongside extraction and anion exchange chromatography to elute high specific activity and chemical purity 203/212Pb in a minimal volume of dilute acid, without the need for evaporation. Optimization of the purification method translated to improvements in radiolabeling yields and apparent molar activity of lead chelators TCMC (S-2-(4-Isothiocyanatobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra(2-carbamoylmethyl)cyclododecane) and Crypt-OH, a derivative of a [2.2.2]-cryptand.https://doi.org/10.1038/s41598-023-37313-8 |
| spellingShingle | Brooke L. McNeil Simona A. Mastroianni Scott W. McNeil Stefan Zeisler Joel Kumlin Sogol Borjian Anthony W. McDonagh Michael Cross Paul Schaffer Caterina F. Ramogida Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine Scientific Reports |
| title | Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine |
| title_full | Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine |
| title_fullStr | Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine |
| title_full_unstemmed | Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine |
| title_short | Optimized production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair for nuclear medicine |
| title_sort | optimized production purification and radiolabeling of the 203pb 212pb theranostic pair for nuclear medicine |
| url | https://doi.org/10.1038/s41598-023-37313-8 |
| work_keys_str_mv | AT brookelmcneil optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT simonaamastroianni optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT scottwmcneil optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT stefanzeisler optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT joelkumlin optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT sogolborjian optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT anthonywmcdonagh optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT michaelcross optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT paulschaffer optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine AT caterinaframogida optimizedproductionpurificationandradiolabelingofthe203pb212pbtheranosticpairfornuclearmedicine |